Yuko Tsuge
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A phase 3 Study of ensitrelvir in japanese participants aged 6-11 years with SARS-CoV-2 infection.
Journal: Journal of the Pediatric Infectious Diseases Society
Published: April 13, 2026
Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review.
Journal: Therapeutic advances in infectious disease
Published: October 17, 2024
Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA® Tablets 125 mg)
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: June 30, 2024
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
Journal: JAMA network open
Published: February 09, 2024
Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.
Journal: Influenza and other respiratory viruses
Published: October 12, 2023
A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Journal: Medicine
Published: February 24, 2023
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Journal: Antimicrobial agents and chemotherapy
Published: September 13, 2022
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 11, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026